Suppr超能文献

人类布鲁氏菌病复发的危险因素。

Risk Factors for Relapse of Human Brucellosis.

作者信息

Hasanjani Roushan Mohammad Reza, Moulana Zahra, Mohseni Afshar Zeinab, Ebrahimpour Soheil

机构信息

Infectious Diseases and Tropical Medicine ResearchCenter, Babol University of Medical Sciences, Babol, Iran.

出版信息

Glob J Health Sci. 2015 Nov 3;8(7):77-82. doi: 10.5539/gjhs.v8n7p77.

Abstract

BACKGROUND & PROPOSE: Brucellosis is serious disease around the world, especially in underdeveloped countries. Relapse is major problem in therapy of brucellosis. This study aimed to evaluate risk factors of relapse after treatment in patients.

METHODS

It is a descriptive-analytic study from 1990 to 2014, in Ayatolla Rohani hospital in Babol, Iran. We studied 980 patients with brucellosis. The studied community included patients infected with brucellosis and the required information was gathered based on their hospital files. The base for recognizing Malta fever were clinical symptoms and Para-clinical sign congruent with infection like as, titer SAT>1:320 and 2-ME>1:160. Patients with relapse and patients without relapse were placed separately in two groups. The data were statistically compared with Spss 16, by Chi-square and Cox -regression tests.

RESULTS

Based on this study, treatment regimen is a preventive factor (P=0.000). Moreover, Based on some statistical methods, regimens no. 3 and 4 were introduce preventive factors (P=0.001) and (P=0.004). It should also be noted that findings the same statistical model, factors like gender, age, residence, professional contacts, complications and delay in treatment were also analyzed but none of them are considered as preventive factors.

CONCLUSION

Based our finding, we suggest aminoglycosides (gentamicin or streptomycin with doxycycline) are associated with lower rate of relapse in brucellosis.

摘要

背景与目的

布鲁氏菌病是一种全球性的严重疾病,在不发达国家尤为突出。复发是布鲁氏菌病治疗中的主要问题。本研究旨在评估患者治疗后复发的危险因素。

方法

这是一项1990年至2014年在伊朗巴博勒的阿亚图拉·鲁哈尼医院进行的描述性分析研究。我们研究了980例布鲁氏菌病患者。研究群体包括感染布鲁氏菌病的患者,所需信息基于他们的医院档案收集。诊断马耳他热的依据是临床症状和与感染相符的亚临床体征,如血清凝集试验(SAT)滴度>1:320和2-巯基乙醇(2-ME)>1:160。复发患者和未复发患者分别分为两组。数据通过卡方检验和Cox回归检验在Spss 16中进行统计学比较。

结果

基于本研究,治疗方案是一个预防因素(P=0.000)。此外,基于一些统计方法,方案3和方案4被确定为预防因素(P=0.001)和(P=0.004)。还应注意的是,在相同的统计模型中,对性别、年龄、居住地、职业接触、并发症和治疗延迟等因素也进行了分析,但它们均未被视为预防因素。

结论

基于我们的研究结果,我们建议氨基糖苷类药物(庆大霉素或链霉素联合强力霉素)与布鲁氏菌病较低的复发率相关。

相似文献

1
Risk Factors for Relapse of Human Brucellosis.人类布鲁氏菌病复发的危险因素。
Glob J Health Sci. 2015 Nov 3;8(7):77-82. doi: 10.5539/gjhs.v8n7p77.
3
Clinical profile and management of brucellosis in Tehran - Iran.
Acta Clin Belg. 2009 Jan-Feb;64(1):11-5. doi: 10.1179/acb.2009.004.
6

引用本文的文献

2
Proteomics Exploration of to Design an Innovative Multi-Epitope mRNA Vaccine.用于设计创新型多表位mRNA疫苗的蛋白质组学探索。
Bioinform Biol Insights. 2024 Aug 30;18:11779322241272404. doi: 10.1177/11779322241272404. eCollection 2024.

本文引用的文献

10
Update on brucellosis: therapeutic challenges.布鲁氏菌病的最新治疗进展:挑战与对策。
Int J Antimicrob Agents. 2010 Nov;36 Suppl 1:S18-20. doi: 10.1016/j.ijantimicag.2010.06.015. Epub 2010 Aug 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验